Insulin, ultra-short acting (insulin aspart, insulin glulisine, insulin lispro)

Generic name
Insulin, ultra-short acting (insulin aspart, insulin glulisine, insulin lispro)
Brand name
ATC Code
A10AB04
Compare …

Insulin, ultra-short acting (insulin aspart, insulin glulisine, insulin lispro)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Diabetes mellitus, insulin-dependent
  • Subcutaneous
    • 1 month up to 18 years

      • Dose depending on the blood sugars


      • Treatment by or after consulting a paediatric specialist (paediatric endocrinologist) who has experience of using insulins.

Renal impaiment in children > 3 months

The insulin requirement may be decreased in cases of reduced renal function. The dosage is adjusted depending on the blood glucose measurements in this case.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Side effects in children are similar to side effects in adults. Injection site lipodystrophy is seen more often in children than in adults. 

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

INSULINS AND ANALOGUES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Insulins and analogues for injection, fast-acting
A10AB01
Insulins and analogues for injection, intermediate-acting
A10AC01
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AD06
A10AD01
Insulins and analogues for injection, long-acting
A10AE

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Novo Nordisk A/S, SPC Novorapid (EU/1/99/119/001;008; 015) 03-02-2016, www.ema.europa.eu, http://www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/human/000258/WC500030372.pdf
  3. Sanofi-Aventis Deutschland GmbH, SPC Apidra (EU/1/04/285/001-004) 26-04-2010, www.geneesmiddeleninformatiebank.nl
  4. Eli Lily Nederland BV, SPC Humalog (EU/1/96/007/008) 28-10-2014, www.geneesmiddeleninformatiebank.nl
  5. Novo Nordisk A/S, SmPC Fiasp (EU 1/16/1160/001-011)26-08-2019
  6. Informatorium Medicamentorum, (Interacties), Geraadpleegd 16 juni 2016
  7. ZorgInstituut Nederand, Farmacotherapeutisch Kompas (Eigenschappen, Contra-Indicaties, Bijwerkingen, Waarschuwingen en Voorzorgen), Geraadpleegd 16 juni 2016
  8. Informatorium Medicamentorum, (Interacties), Geraadpleegd 16 juni 2016
  9. ZorgInstituut Nederand, Farmacotherapeutisch Kompas (Eigenschappen, Contra-Indicaties, Bijwerkingen, Waarschuwingen en Voorzorgen), Geraadpleegd 16 juni 2016
  10. ZorgInstituut Nederand, Farmacotherapeutisch Kompas (Eigenschappen, Contra-Indicaties, Bijwerkingen, Waarschuwingen en Voorzorgen), Geraadpleegd 16 juni 2016
  11. Informatorium Medicamentorum, (Interacties), Geraadpleegd 16 juni 2016

Changes

Therapeutic Drug Monitoring


Overdose